Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Pfizer

These stocks could be ready for big bounces.

3 Beaten-Down Stocks to Buy and Hold

NEW YORK , Oct. 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline. SO WHAT: If you purchased Abbott securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors With Losses to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT

NEW ORLEANS , Oct. 14, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period").

ABBOTT LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

New York, New York--(Newsfile Corp. - October 14, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline.

ROSEN, A TOP RANKED FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT

Abbott, the baby formula manufacturer, said Friday it's recalling some lots of its "ready-to-feed" liquid products and formulas in 2-ounce containers. A "small percentage" of the bottles may not have been sealed properly, Abbott said.

Abbott Issues New Baby Formula Recall

Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Abbott (ABT) Could Beat Earnings Estimates Again

Johnson & Johnson

Are investors better off waiting until next year to buy stocks?

Why the Bear Market May Not Be Over Anytime Soon

Flu and virus seasons have become more unpredictable with the addition of COVID-19 The Home Edit and Abbott aim to bring peace of mind to families when it comes to their health by organizing medicine cabinets in time for the cold and flu season Rapid at-home tests remain an important health tool for COVID-19, providing fast and reliable results ABBOTT PARK, Ill., Oct. 12, 2022 /PRNewswire/ -- As we enter cold and flu season amid continuing COVID-19 cases, Abbott (NYSE: ABT), makers of BinaxNOW™ COVID-19 Antigen Self Test, and The Home Edit, the world's number one organizational company and a global lifestyle brand, are partnering to redesign the medicine cabinet for today's health needs.

Abbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season

Supply chain disruptions, forex headwinds, and a decline in Covid-19-related demand will likely weigh on the company's performance.

Will Abbott Stock Rise After Its Q3 Results?

New York, New York--(Newsfile Corp. - October 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline.

ROSEN, Leading Investor Counsel, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT

AbbVie

It's parent vs. child in this bear-market matchup.

Better Bear-Market Buy: Abbott Laboratories vs. AbbVie Stock

New York, New York--(Newsfile Corp. - October 9, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline.

ROSEN, Top Ranked Investor Counsel, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT

DexCom

Medtronic

These companies are three of the leading manufacturers of continuous glucose monitoring systems.

3 Diabetes Care Stocks That Could Help Set You Up for Life

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Abbott and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abbott Laboratories - ABT

NEW ORLEANS , Oct. 7, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of Illinois.

ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

NEW YORK , Oct. 7, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline. SO WHAT: If you purchased Abbott securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT

San Francisco, California--(Newsfile Corp. - October 7, 2022) - Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now.Class Period: Feb. 19, 2021 - June 8, 2022Lead Plaintiff Deadline: Oct. 31, 2022Visit: www.hbsslaw.com/investor-fraud/ABTContact An Attorney Now: ABT@hbsslaw.com844-916-0895Abbott Laboratories (NYSE: ABT) Securities Fraud Class Action: The action challenges Defendants' statement and omissions concerning what the FDA called "egregiously unsanitary" condit

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending

Randomized clinical trial of Abbott's FreeStyle Libre 2 system compared to self-monitoring of blood glucose (SMBG) shows FreeStyle Libre 2 leads to significant reductions in glycated hemoglobin (HbA1c) levels at 24 weeks in people with Type 1 diabetes and sub-optimal glycemic control1 People using the FreeStyle Libre technology had average HbA1c levels a significant 0.5% lower than those using SMBG at the end of the study period1 The FreeStyle Libre 2 system use was also linked to improvements in overall satisfaction and reduced burden associated with glucose monitoring1 ABBOTT PARK, Ill., Oct. 6, 2022 /PRNewswire/ -- A new study published in The New England Journal of Medicine finds that for adults with Type 1 diabetes and sub-optimal glycemic control, Abbott's FreeStyle Libre® 2 glucose monitoring system provided significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose (SMBG), which were sustained for the study duration of 24 weeks.1 Use of the FreeStyle Libre 2 system was also linked to improvements in participant-reported quality of life outcomes, including overall satisfaction and reduction in burden associated with glucose monitoring.

New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life

CVS Health

The payouts these companies distribute every quarter could surge over the next several years.

3 Dividend Stocks to Buy In October and Hold Forever

New York, New York--(Newsfile Corp. - October 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline.

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT

NEW ORLEANS , Sept. 30, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.

ABBOTT LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

Acadia Healthcare

AstraZeneca

Bristol-Myers

Cardinal Health

Cigna

Merck

Novavax

Novartis

Regeneron Pharmaceuticals

Teladoc

UnitedHealth Group

Health care stocks are traditionally a defensive play for investors in a falling market. It's a rich market with blue chip insurance providers, service providers, pharmaceutical companies, retailers, and tech players.

Health Care Stocks: Reviewing The Best Of The Industry

San Francisco, California--(Newsfile Corp. - September 28, 2022) - Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now.Class Period: Feb. 19, 2021 - June 8, 2022Lead Plaintiff Deadline: Oct. 31, 2022Visit: www.hbsslaw.com/investor-fraud/ABTContact An Attorney Now: ABT@hbsslaw.com 844-916-0895Abbott Laboratories (NYSE: ABT) Securities Fraud Class Action: The action challenges Defendants' statement and omissions concerning what the FDA called "egre

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys Before October Application Deadline in Securities Fraud Class Action

NEW YORK , Sept. 28, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT

BioNTech SE

Co-Diagnostics

Valneva SE

As people acclimatize to the new normal, it's time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.

News for Abbott Labs Stock (ABT)